Abstract
A series of 16 novel 4-(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)-6-(substituted-phenyl)pyrimidin-2-ol analogues was synthesized in satisfactory yields after toxicity prediction and drug score studies by Osiris software followed by anti-inflammatory, analgesic, ulcerogenic, and lipid peroxidation activities of 10 compounds by the known reported methods. 4-(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)-6-(4-chlorophenyl)pyrimidin-2-ol (6g) was found to be a potent compound of the series showed good anti-inflammatory (81.91 ± 7.69 % inhibition) and analgesic activity (53.25 ± 2.91) with less ulcerogenic effects (0.66 ± 0.40).
Keywords: Anti-inflammatory activity, Analgesic activity, Osiris software, Pyrazole, Ulcerogenicity.
Letters in Drug Design & Discovery
Title:Synthesis of 4-(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)-6-(substituted phenyl)pyrimidin-2-ol Analogues as Anti-Inflammatory and Analgesic Agents
Volume: 10 Issue: 8
Author(s): Muhammad Jahangir Alam, Mohamed Jawed Ahsan, Ozair Alam and Suroor Ahmad Khan
Affiliation:
Keywords: Anti-inflammatory activity, Analgesic activity, Osiris software, Pyrazole, Ulcerogenicity.
Abstract: A series of 16 novel 4-(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)-6-(substituted-phenyl)pyrimidin-2-ol analogues was synthesized in satisfactory yields after toxicity prediction and drug score studies by Osiris software followed by anti-inflammatory, analgesic, ulcerogenic, and lipid peroxidation activities of 10 compounds by the known reported methods. 4-(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)-6-(4-chlorophenyl)pyrimidin-2-ol (6g) was found to be a potent compound of the series showed good anti-inflammatory (81.91 ± 7.69 % inhibition) and analgesic activity (53.25 ± 2.91) with less ulcerogenic effects (0.66 ± 0.40).
Export Options
About this article
Cite this article as:
Alam Jahangir Muhammad, Ahsan Jawed Mohamed, Alam Ozair and Khan Ahmad Suroor, Synthesis of 4-(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)-6-(substituted phenyl)pyrimidin-2-ol Analogues as Anti-Inflammatory and Analgesic Agents, Letters in Drug Design & Discovery 2013; 10 (8) . https://dx.doi.org/10.2174/15701808113100890022
DOI https://dx.doi.org/10.2174/15701808113100890022 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Paliperidone Use in the Elderly
Current Drug Safety Treating High Density Lipoprotein Cholesterol (HDL-C): Quantity Versus Quality
Current Pharmaceutical Design Connexins in Renal Endothelial Function and Dysfunction
Cardiovascular & Hematological Disorders-Drug Targets Monoclonal Antobodies: Application in Radiopharmacy
Current Radiopharmaceuticals Anti-Hypertensive Potential and Epigenetics of Angiotensin II type 2 Receptor (AT2R)
Current Hypertension Reviews New-Generation, Non-SSRI Antidepressants: Therapeutic Drug Monitoring and Pharmacological Interactions. Part 1: SNRIs, SMSs, SARIs
Current Medicinal Chemistry Inflammatory Caspases: Targets for Novel Therapies
Current Pharmaceutical Design Immunotherapy in Bladder Cancer
Current Molecular Pharmacology Cardioprotective effects of Aronia melanocarpa anthocynanins. From laboratory experiments to clinical practice.
Current Pharmaceutical Design Drugs Used to Treat Parkinsons Disease, Present Status and Future Directions
CNS & Neurological Disorders - Drug Targets Photodynamic Therapy: The Light Treatment for Cutaneous Non- Melanoma Malignancies
Current Cancer Therapy Reviews Endothelin Receptors in Gastrointestinal Smooth Muscle
Current Protein & Peptide Science Prognostic Significance of Risk Factors and Biomarkers in Patients Hospitalized for Cardiorenal Syndromes: A Pilot Study
Current Medicinal Chemistry L-Arginine Transport and Nitric Oxide Production in Kinin Receptor B1-/- Endothelial Cells.
Protein & Peptide Letters Effects of Antiplatelet Medication on Arteriovenous Fistula Patency After Surgical Thrombectomy
Current Vascular Pharmacology Pharmacogenetics of the Human MDR1 Multidrug Transporter
Current Pharmacogenomics Design, Synthesis and Biological Evaluation of Benzopyran Derivatives as KATP Channel Openers
Letters in Drug Design & Discovery Emerging Role of Cetuximab in the Treatment of Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Ligand-Based Peptide Design and Combinatorial Peptide Libraries to Target G Protein-Coupled Receptors
Current Pharmaceutical Design Effects of N-Acetyl-L-Cysteine and Hyaluronic Acid on HBOC-201- Induced Systemic and Cerebral Vasoconstriction in the Rat
Current Drug Discovery Technologies